Renal Cell Carcinoma

RENAL CELL CARCINOMA ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

COSMIC-313: Triplet Prolongs PFS vs Doublet in Renal Cell Carcinoma

The PFS benefit was driven primarily by patients with intermediate-risk disease.
Adjuvant Nivolumab-Ipilimumab Failed to Improve DFS in Renal Cell Carcinoma

Nivolumab plus ipilimumab did not prolong disease-free survival, and 43% of patients discontinued treatment due to toxicities.
Previous Cannabis Use Linked to Lower Risk of Some Genitourinary Cancers

A new study suggests that previous use of cannabis is associated with a lower risk of certain genitourinary cancers.
Cabozantinib Demonstrates Activity in Advanced Translocation Renal Cell Carcinoma

Cabozantinib can produce durable responses in patients with advanced MiT family translocation renal cell carcinoma, a new study suggests.
Normonatremia Tied to Outcomes in Metastatic Renal Cell Carcinoma

Serum sodium levels in the lower end of the normal range are associated with inferior outcomes in metastatic renal cell carcinoma, a study suggests.

RENAL CELL CARCINOMA NEWS

Surgery

Cytoreductive Nephrectomy Added to ICI Therapy Ups Survival in mRCC

November 15, 2022

Gut bacteria

Researchers Characterize Gut Microbiome of Patients With mRCC and Sarcopenia

November 8, 2022

Live Bacterial Product Improves Outcomes in Metastatic Renal Cell Carcinoma

November 7, 2022

Doctor showing clipboard to patient

RCC Trials Use “Potentially Excessive” Exclusion Criteria

November 6, 2022

DNA

Characteristics of Renal Cell Carcinoma Differ According to Genetic Ancestry

November 6, 2022

Next post in Renal Cell Carcinoma

Ipi-Nivo and Axi-Pembro Produce Similar OS as Frontline Therapy in Metastatic RCC